1. Scrip
  2. >>New Products

And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer

 
• By Jessica Merrill and Mandy Jackson

Lilly will be offering its Verzenio – the third CDK4/6 inhibitor to reach the US market – at a comparable list price to Pfizer's Ibrance and Novartis' Kisqali. FDA granted the drug a swift approval, just two months after it was accepted for priority review.

Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.

Eli Lilly & Co.'s Verzenio (abemaciclib), now approved for breast cancer, will compete for market share in a crowded category that already includes two rival cyclin dependent kinase 4/6 (CDK4/6) inhibitors – Pfizer Inc.'s well-entrenched Ibrance (palbociclib) and Novartis AG's newcomer Kisqali (ribociclib) – but it isn't setting out to do so based on price.

The US FDA approved Verzenio on Sept. 28, just two months after Lilly completed its new drug application (NDA) filing,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Scrip

Asia Deal Watch: JXR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.